Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.

Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. J Clin Pharmacol. 2020 10; 60(10):1324-1333.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Breast Neoplasms
Dose-Response Relationship, Drug
Female
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Humans
Maximum Tolerated Dose
Middle Aged
Phthalazines
Poly(ADP-ribose) Polymerase Inhibitors
Proportional Hazards Models
Time Factors
Treatment Outcome

authors with profiles

JENNIFER LITTON